V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220013685 | 220008112 | 1.88 | 87.1 | Curative (C) | 2016-04-24 | 2016-08-14 | AML18 PILOT TRIAL | Y | N | 220030863 | PILOT TRIAL |
| 220013686 | 220008113 | 1.75 | 0 | Disease modification (D) | 2013-05-16 | 2015-04-07 | Rituximab | N | N | 220030865 | RITUXIMAB |
| 220013687 | 220008114 | 1.56 | 0 | Palliative (P) | 2017-08-17 | 2017-08-17 | Dasatinib | N | N | 220030868 | DASATINIB |
| 220013688 | 220014429 | null | null | Curative (C) | 2014-07-09 | 2015-06-03 | Dasatinib | null | N | 220030871 | DASATINIB |
| 220013689 | 220008115 | 1.73 | 81.3 | Curative (C) | 2017-10-15 | 2017-12-29 | AML 18 TRIAL | Y | N | 220030873 | AML18 TRIAL |
| 220013690 | 220008115 | 1.66 | 113.8 | Curative (C) | 2017-11-04 | 2017-11-17 | AML 18 TRIAL | N | null | 220030873 | AML18 TRIAL |
| 220013691 | 220008117 | 1.59 | 60.7 | Neo-adjuvant (N) | 2013-07-16 | 2013-07-16 | Dasatinib | 02 | N | 220030880 | DASATINIB |
| 220013692 | 220019809 | null | 70.6 | Curative (C) | 2017-01-13 | 2017-01-27 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220030885 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013693 | 220008118 | null | null | Curative (C) | 2016-01-18 | 2016-01-18 | Rituximab | N | null | 220030886 | RITUXIMAB |
| 220013694 | 220008118 | 1.65 | 0 | Palliative (P) | null | 2014-09-13 | AML 18 TRIAL | N | N | 220030886 | AML18 TRIAL |
| 220013695 | 220017877 | 1.88 | 79.6 | Curative (C) | 2013-07-31 | 2013-09-03 | Rituximab | N | null | 220030888 | RITUXIMAB |
| 220013697 | 220008120 | 1.69 | 60.8 | Curative (C) | 2013-08-16 | 2013-11-06 | AML 18 Pilot Trial | Y | N | 220030896 | PILOT TRIAL |
| 220013698 | 220008121 | 1.71 | null | Not known (9) | 2014-10-11 | 2014-10-11 | Rituximab | 02 | N | 220030898 | RITUXIMAB |
| 220013699 | 220014435 | 1.58 | 57.8 | Curative (C) | null | 2015-12-24 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 220030901 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013701 | 220008125 | 0 | null | Curative (C) | 2017-05-19 | 2017-05-30 | AML 18 TRIAL | 01 | N | 220030906 | AML18 TRIAL |
| 220013702 | 220008127 | null | null | Disease modification (D) | null | 2017-01-23 | Rituximab | 02 | N | 220030913 | RITUXIMAB |
| 220013703 | 220014438 | null | null | Palliative (P) | 2014-09-24 | 2014-09-29 | Dasatinib | N | N | 220030915 | DASATINIB |
| 220013705 | 220008130 | 1.79 | null | Disease modification (D) | 2013-12-08 | 2013-12-10 | Dasatinib | 99 | null | 220030919 | DASATINIB |
| 220013706 | 220008132 | 1.71 | 80.75 | Curative (C) | 2014-10-13 | 2014-10-23 | AML 18 TRIAL | Y | N | 220030921 | AML18 TRIAL |
| 220013707 | 220008133 | 1.75 | 58.9 | Curative (C) | 2013-12-18 | 2013-12-21 | AML 18 TRIAL | N | N | 220030929 | AML18 TRIAL |
| 220013708 | 220008134 | 1.8 | null | Palliative (P) | 2013-09-02 | 2014-09-18 | Dasatinib | 2 | N | 220030929 | DASATINIB |
| 220013709 | 220008135 | 1.84 | 87.5 | Curative (C) | 2017-07-19 | 2017-07-19 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220030936 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013710 | 220008136 | null | 62.5 | Curative (C) | 2017-04-23 | 2017-08-02 | AML18 PILOT TRIAL | Y | N | 220030936 | PILOT TRIAL |
| 220013711 | 220014442 | null | 54.8 | Curative (C) | 2015-10-18 | 2016-04-01 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 220030939 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013712 | 220019810 | 1.61 | 44.4 | Curative (C) | 2014-02-27 | 2014-03-17 | AML 18 TRIAL | Y | N | 220030945 | AML18 TRIAL |
| 220013713 | 220014443 | 1.68 | 0 | Curative (C) | null | 2015-02-13 | Dasatinib | N | N | 220030950 | DASATINIB |
| 220013714 | 220008140 | 1.66 | 66 | Curative (C) | 2016-05-18 | 2016-09-07 | Dasatinib | 2 | N | 220030950 | DASATINIB |
| 220013715 | 220008141 | null | 41 | Palliative (P) | 2018-08-19 | 2018-08-19 | Dasatinib | N | null | 220030955 | DASATINIB |
| 220013718 | 220008151 | 1.6 | 57.8 | Curative (C) | 2014-07-26 | 2014-08-17 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 220030960 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013719 | 220014450 | 1.48 | 63.5 | Neo-adjuvant (N) | 2013-04-12 | 2013-10-11 | Dasatinib | 02 | N | 220030962 | DASATINIB |
| 220013720 | 220008155 | null | 82 | Curative (C) | 2014-05-22 | 2014-05-22 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 220030962 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013721 | 220017886 | null | 93.15 | Curative (C) | 2013-11-13 | 2013-11-13 | Alemtuz+Fludara+Melphalan RIC MUD | null | N | 220030966 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013722 | 220008156 | 1.6 | 65.2 | Palliative (P) | 2016-08-14 | 2016-08-15 | Dasatinib | N | N | 220030970 | DASATINIB |
| 220013723 | 220008157 | 1.7 | 61.8 | Curative (C) | 2013-10-10 | 2014-01-19 | AML 18 TRIAL | Y | N | 220030971 | AML18 TRIAL |
| 220013724 | 220014453 | null | 59 | Curative (C) | 2017-11-03 | 2017-11-03 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220030973 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013725 | 220014453 | 1.7 | null | Curative (C) | 2016-03-30 | 2016-04-05 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 220030973 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013726 | 220008159 | 1.66 | null | Curative (C) | 2015-02-17 | 2015-05-11 | Dasatinib | 99 | N | 220030977 | DASATINIB |
| 220013727 | 220008160 | 1.61 | 72.8 | Palliative (P) | 2018-04-24 | 2018-05-11 | Rituximab | N | N | 220030983 | RITUXIMAB |
| 220013728 | 220008162 | 1.65 | 58.5 | Curative (C) | 2014-06-03 | 2014-06-03 | AML 18 TRIAL | 1 | N | 220030983 | AML18 TRIAL |
| 220013729 | 220019816 | 1.8 | null | Disease modification (D) | 2016-01-29 | 2016-02-02 | Rituximab | 2 | N | 220030988 | RITUXIMAB |
| 220013730 | 220008163 | 1.66 | 100 | Curative (C) | 2018-11-05 | 2018-11-08 | AML 18 TRIAL | N | null | 220030991 | AML18 TRIAL |
| 220013735 | 220008173 | 1.74 | 103.8 | Curative (C) | 2018-01-17 | 2018-01-20 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220031003 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013736 | 220014458 | 1.88 | 68 | Disease modification (D) | 2015-09-09 | 2015-09-09 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 220031003 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013737 | 220008174 | null | 73 | null | 2015-11-06 | 2015-12-27 | AML 18 TRIAL | 01 | null | 220031014 | AML18 TRIAL |
| 220013738 | 220008174 | 1.49 | 70.1 | Curative (C) | 2017-02-08 | 2017-02-09 | AML 18 TRIAL | Y | null | 220031014 | AML18 TRIAL |
| 220013739 | 220008174 | 1.84 | 114 | Curative (C) | 2017-09-19 | 2017-10-20 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220031014 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013740 | 220017893 | 1.62 | null | Palliative (P) | 2019-01-12 | 2019-01-12 | Dasatinib | 2 | null | 220031027 | DASATINIB |
| 220013741 | 220021898 | 1.58 | 78 | Curative (C) | 2016-03-21 | 2016-03-26 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220031038 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013742 | 220008176 | 1.96 | 95 | Curative (C) | 2017-03-17 | 2017-03-25 | Alemtuz+Fludara+Melphalan RIC MUD | N | null | 220031040 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220013743 | 220014461 | 1.67 | 54 | Disease modification (D) | 2014-04-28 | 2014-04-29 | Rituximab | null | N | 220031045 | RITUXIMAB |